The EXHALYZER® D was successfully used for multiple breath washout (MBW) tests on an 11 months old infant. This was reported in a case report presented at the 22. German Mucoviscidosis congress in Würzburg, Germany by T. Fuchs and H. Ellemunter from Innsbruck, Austria.
The subject was diagnosed with cystic fibrosis (CF) at the age of 6.5 weeks. Due to poor weight development in the 6th month, the option to start a modulator therapy with Ivacaftor (by Vertex Pharmaceuticals Inc.) was discussed with the parents, who agreed to start the treatment at age 11 months, although Ivacaftor is only approved for patients age 12 months and older. MBW tests were performed at start of treatment, as well as 2, 4 and 16 weeks after. The MBW tests showed a clear improvement of the Lung Clearance Index (LCI). Together with other investigated parameters, the MBW tests perfomed on the EXHALYZER® D proved the effectiveness of the Ivacaftor therapy in patients as young as 11 months.

For more information, see page 39 of the following publication: